Research Paper · Canine Parvovirus (CPV)
Four-arm antiviral trial in canine parvovirus (interferon-omega performed best, 85.7% survival)
Why it matters: This head-to-head trial established the 85.7% interferon-omega survival benchmark used for comparison against TrueTect CPMA on the parvo clinical update page.
Open access, CC BY-NC
This page is part of the Dog Health Research Hub, a DOI-linked reference library for canine parvovirus and canine distemper research, curated by Annette Thompson, a medical technologist, not a veterinarian. Provided for clinical information only; treatment decisions belong with a qualified veterinarian who knows the individual patient.